Objective: Magnolia bark contains magnolol, metabolized to tetrahydromagnolol and honokiol, with both GABA-ergic/cannabimimetic activities, hence of possible attraction to vulnerable individuals/recreational misusers.
| INTRODUCTION
Magnolia officinalis is part of the Magnoliaceae family; its bark contains magnolol and honokiol (Lee et al., 2012; Watanabe, Ikegami, & Horie, 2002) , respectively identified in ratios of approximately 4:1 (Kotani, Kojima, Hakamata, Jin, & Kusu, 2005; Tsai & Chen, 1992) , together with α-/β-/γ-eudesmol and methyleugenol (Wrigley, 2009 ).
Magnolia bark-containing preparations (Houpo or Koboku; for a thorough review of the issue, see Lee et al., 2011; and Wrigley, 2009) have a role in both Chinese and Japanese traditional herbal medicine (Rempel et al., 2012; Xu et al., 2008) , reportedly possessing a range of activities, including: antioxidant, anti-inflammatory/antibacterial, antithrombotic/anti-platelet, hypoglycaemic, smooth muscle relaxant (Sohn, Kim, Kim, et al., 2007; Squires, Ai, & Witt, 1999) , weight control (Garrison & Chambliss, 2006) , anti-dyspeptic/prokinetic (Oikawa, Ito, Koyama, & Hanawa, 2005) , antiepileptic (Chiou, Ling, & Chang, 1997) , and hepato-protective (Lee et al., 2012) .
The mechanisms underlying Magnolia compounds' central pharmacological activities are not clear (Lee et al., 2011) . Magnolol is a partial agonist at both endocannabinoid receptor subtypes (CB1 and CB2); with a higher potency at CB2 (Ki 1.44 ± 0.10 μM) as opposed to CB1 (Ki 3.15 ± 1.65 μM; Rempel et al., 2012) .
Tetrahydromagnolol (THM), the main faecal magnolol metabolite, is still active both as a full CB1 agonist and as a CB2 partial agonist (e.g., CB1 Ki 2.26 ± 0.89 μM; CB2 Ki 0.416 ± 00.89 μM; Rempel et al., 2012 ). Furthermore, honokiol shows full agonist properties at CB1 receptors, whilst acting as antagonist/inverse agonist at the CB2 receptor subtype. Hence, magnolol, honokiol, and THM show higher intrinsic activity at CB1 than tetrahydrocannabinol (THC), the main cannabis euphoriant compound (Fattore, 2016) . Magnolia compounds' interaction with gamma-aminobutyric acid-A/GABA-A and muscarinic receptors (Lin, Chen, & Ko, 2007; Squires et al., 1999 ) may be consistent with reducing anxiety levels observed in small-scale clinical studies (Kalman et al., 2008; Mantani et al., 2002) . Indeed, in animal behavioural models, honokiol and dihydrohonokiol are described as producing anxiolytic, diazepam-like effects (Alexeev, Grosenbaugh, Mott, & Fisher, 2012; Kuribara, Stavinoha, & Maruyama, 1998) .
Conversely, the magnolol/honokiol antidepressant-like activities observed in preclinical models may be associated with alterations in serotonin turnover in the frontal cortex, striatum, and nucleus accumbens (Nakazawa, Yasuda, & Ohsawa, 2003) .
Magnolol and honokiol seem to have similar pharmacokinetic characteristics, with half lives being both almost dose-independent and of first order (Lee et al., 2011) . Both compounds can readily pass the blood brain barrier (Tsai, Chou, & Chen, 1996; Wang et al., 2011) ; magnolol oral bioavailability is in the region of 10% (Wrigley, 2009 ) and is extensively metabolized in the liver, with glucuronides being its major metabolites. Similarly, glicuronidation and sulphation are the main metabolic pathways for honokiol (Böhmdorfer et al., 2011; Hattori et al., 1986) .
Magnolia derivatives' could interact with other sedatives, increasing the risk of drowsiness/motor reflex depression (Wrigley, 2009 ).
Although high-dosage magnolol may induce in vitro hepatotoxicity (Kao et al., 2010) , acute/long-term preclinical/clinical toxicity studies have not identified any biological alterations associated with Magnoliabased (including mints/gums) preparations' intake (Liu et al., 2007; Wrigley, 2009 ). However, tremors, peri-labial numbness, sexual and thyroid dysfunction, fatigue, and headache have been anecdotally reported by small numbers of Magnolia users (Kalman et al., 2008) .
Magnolia GABA-ergic and cannabimimetic activities could arguably be of attraction to vulnerable individuals or recreational misusers.
Hence, we aimed here at reviewing the literature relating to Magnolia compounds' misusing issues; assessing the Magnolia bark/derivatives' possible misuse potential whilst considering the related anecdotal online reports; and providing an overview of the Magnolia online acquisition possibilities from both English-and Italian-language websites.
| MATERIALS AND METHODS
To identify the peer-reviewed papers commenting on Magnolia misuse issues, a comprehensive search on the Embase, Scopus, Google Scholar, and Pubmed/Medline databases was performed using the following keywords: (Magnolia) AND (abuse OR misuse OR poisoning OR dependence OR addiction). No language or time restrictions were placed on the electronic search; focus was on clinical data only and covered the period up to March 15, 2017.
To identify information on Magnolia misusers' first-hand experiences, a qualitative/observational approach on selected websites was carried out. In doing so, between January 2014 and March 2016, a range of qualitative Google searches were carried out, both in English and in Italian, using keywords such as "Magnolia and abuse," "Magnolia and misuse," and "Magnolia and experience." The first 2 pages/20 hits per keyword (e.g., 60 per language; e.g., 120 links) were considered. A number of websites were excluded, since: not relevant (e.g., referring to Magnolia role in gardening); being duplicates; or requiring a registration/payment procedure. Conversely, a range of fora posts/threads relating to a few Magnolia themes, including psychoactive effects, dosage/intake modalities, tolerance/withdrawal, untoward effects, and use in combination with other psychoactive compounds were specifically analyzed. No posts/other contributions to fora discussions were made, and no information or clarification of content was sought by the researchers.
To obtain an overview of Magnolia products' online purchase possibilities, a range of Google searches in English and Italian were carried out, using the "Magnolia bark to buy;" and "Magnolia bark purchase" keywords. The information provided by the identified links on safety, consumer reviews, and purchasing costs were analyzed. 
| RESULTS
No peer-reviewed papers relating to Magnolia abuse/misuse/ dependence/addiction were here identified. Conversely, some 41 websites relating to Magnolia issues were here assessed, with most (e.g., 21) being dedicated to its purchase/acquisition. A further 13 websites included specific/illustrative comments on the Magnolia compounds' associated psychoactive effects. Analysis of the 137 relating posts identified from here showed that, in most (e.g., n = 133) cases, users were commenting on the Magnolia-related anxiolytic/sedative effects, whilst n = 4 posts emphasized its cannabimimetic/recreational effects. Further reasons to self-administer with Magnolia included achievement of antidepressant, analgesic, anti-nausea, and weight control effects (see Table 1 ). Specifically, three groups of Magnolia misusers were here tentatively identified: (a) subjects with a psychiatric history, self-administering with Magnolia as a sleeping aid, as a "natural alternative" to prescribing sedatives or to cope with benzodiazepines' withdrawal; (b) subjects with a polydrug misuse history, allegedly ingesting Magnolia to enhance/modulate the effects of cannabimimetic To "chill out"; alone or in association with alcohol "... couple scoops of magnolia bark extract after work are perfect for chilling for the rest of the evening ..." (Amazon.com) "…real good with a few beers, especially at the end of a long day …"
To use as a safer alternative of phenibut "... I had heard great things about phenibut for social anxiety, but not-so-great things about withdrawal/ dependance, and I needed something mild enough that I could take it at work or driving without looking or feeling "on something". So I settled on this magnolia bark extract, and like many of the other reviewers find it effective ..." (Amazon.com) "….I purchased this product to use as a supplement to phenibut, as you can not use phenibut often without risks …. phenibut can be a little too strong sometimes……Magnolia bark fits those needs for me…. .. can double the effects of phenibut (truly, i have tried this with others and they agree).They quoted 2 to 5 times potentiation i think. My brother said he noticed a 75% increase, for me it is a doubling effect ..." (forum.mindandmuscle.net) "….Magnolia Bark Extract works well for relaxation purposes. I would try the Magnolia Bark extract on its own before adding it to Ambien (e.g. zolpidem) + Kratom, because the effect could be strongly synergistic…" (Drugs-forum.com) "….It felt kind of like a muscle relaxer when I smoked cannabis….I took about 10 mg and placed it over a bowl of cannabis (Michiganmedicalmarijuana.org) "... SWIM would imagine that with Spice Tropical Synergy the honokiol and magnolol in the magnolia bark synergises with the effects of the JWH-018 too ..." (Drugs-forum.com) "…..I found it to be an especially good adjunct for using with cognitive enhancers, like hydergine or lucidril, as it seemed to balance out their stimulating properties…." (Amazon.com) "….ashwaghanda and magnolia I find to be good and not causing any extra anxiety or withdrawal problems. …. Anyway I recently ordered some magnolia bark along with some 98% honokiol extract and I'm gonna mix the two….. Also ordered Mulungu which Ive heard good things about, possibly Kanna though I'm a bit weary of kanna since it might have ssri action and I seem to be sensitive to that. I agree with who ever said mixing some bacopa and rhodiola together, as I've had some good results mixing this with the magnolia and ashwaghanda. …." (Longecity.org) "…..Is very effective for reducing Kratom's nausea…." (Drugs-forum.com)
Experience reports "… 8:30 pm -Swim put the 50 mg of isolate in a glass of water and drank. 9:02 pm -Swim noticed a little something in the back of his mind which can only be described as a flash of complete tiredness/pure disreguard for my surroundings (this could have been placebo effect, not sure it was very short in duration, maybe 10-20secs) 9:17 pm -What was once a flash is now steady. Swim says he feels relaxed and at the same time he feels a disreguard for his surrounding or anything that may have been troubling him in the day. 9:37 pm -Peak was reached, Swim said he still feels relaxed but the feeling of disreguard has subsided slightly. 9:45 pm -Swim decided to does with another 50 mg of isolate. 10:22 pm -Swim once again slightly feels disreguard for surroundings. 10:53 pm -Swim feels like some of his everyday problems seem to not matter as much. Things just seem trivial (Continues)
"Spice" drugs and/or of other GABA-ergic molecules, especially phenibut and gammahydroxybutyrate. A range of herbs/plants, including Mytragina speciosa (Kratom), and Sceletium tortuosum (Kanna) were here reportedly co-administered with Magnolia (see Table 1 ); and (c) subjects naive to the misusing drugs' scenario, perceiving Magnolia either as a natural dietary supplement or as an affordable way to lose weight.
Misuse of magnolia bark compounds mostly seemed to occur orally, with smoking and vaporizing intake techniques being also reported, at dosages in the range of 60-900 mg. Adverse, transient, untoward effects included mouth/throat numbness, lightheadedness/ tiredness, and dizziness. Although specific withdrawal symptoms
were not described, levels of tolerance were anecdotally reported (see Table 1 ). "……i take about 600 mg to 800 mg at a time, any less doesn't do much…." (Amazon.com) "…not to be taken sublingually…" (Amazon.com) "….i use it with Coconut Milk (source of fat for enhanced absorption) and its pretty tasty as long as only using a small amount…… I have tried using Magnolia Bark Extract sublingually at approximately 200 mg…. it killed the taste buds on the front half of my tongue. I could no longer taste even pure salt. It tasted like beach sand….." (Drugs-forum.com)
Withdrawal, tolerance, and side effects "….magnolia i find to be good and not causing any extra anxiety or withdrawal problems…." (Longecity.org) "…One thing I did notice about magnolia bark extract is if you take it two days in a row, the second day isn't as good as the first day…" (Drugs-forum.com) " ….The only problem with the extract, for me at least, is that it starts to loss some of its magic with frequent use, so I just use it one or twice a week …" (Amazon.com) ".I have recently tried Lift Mode Magnolia bark powder -put in hot water and drank. It caused entire mouth and throat to go numb; then next day became extremely sore as though burnt…." (Webmd.com) "……..I was taking 200 mg for 8 days and developed vertigo one morning. After about a week the vertigo seems to have stopped, but I still have a mild ringing in the ears and feel light headed at times…." (herbwisdom.com)
A vast range of Magnolia vending websites, especially when searching in English, was identified. Branded with various commercial names, Magnolia derivatives were offered either as pure concentrates/ extracts or mixed with other substances. Overall, these commercial websites labelled their products as "safe," "legal," and "pure," whilst describing themselves as "verified merchants," offering a "100% Poland, the United States, the Philippines, Georgia, and Panama.
Similarly, the "Magnolia + purchase" and "Magnolia Bark" queries increased over the last couple of years, with searches mainly deriving from the United States, Singapore, India, Australia, and the Philippines. The Web plays a huge role in the modification of both psychotropics' availability and changes in drug scenarios (Schifano, Orsolini, & Papanti, 2015; Schifano, Papanti, Orsolini, & Corkery, 2016) , and one could argue that the vast levels of Magnolia online acquisition possibilities may reflect the large number of potential customers. Indeed, the recent increase of Magnolia popularity, mainly a sedative, here identified may arguably be due to its peculiar pharmacological properties, acceptable affordability levels, virtually worldwide favourable legal status, and customers' attraction to a product being perceived as "natural" and hence somehow "safe."
Although no peer-reviewed papers focussing on the prevalence levels of possible magnolols' compounds use/misuse were identified, the Google Trends approach provided here some data of possible interest. Overall, possibly due to the searches having been carried out with this language, a range of Magnolia-related searches are derived from English-speaking countries (e.g., the United States, Australia, Canada, and the United Kingdom), the Philippines, and India.
Conversely, it is of interest that the honokiol/magnolol misuse-related queries are mainly derived from a range of eastern European regions (e.g., Bulgaria, Slovakia, Poland, and Romania), an issue which should deserve further research attention in the future.
The pharmacological effects of magnolol, THM, honokiol, and 4-O-methylhonokiol might be used as a new generation of antiabstinence, anti-craving, and neuroprotective drugs, with their GABA-ergic activity possibly being useful as well for the treatment of convulsions, spasms, and associated pain (Coppola & Mondola, 2014) .
Conversely, in considering magnolol/THM cannabimimetic properties, recent work has shown that is possible to design and synthesize a series of (TH) magnolol analogues with extremely high CB1 receptor affinity, selectivity, efficacy, and potency (Fuchs, Rempel, & Muller, 2013) .
Indeed, this is the case of the dual CB1/CB2 full agonist 2-(2-methoxy-5-propyl-phenyl)-4-hexylphenol (Ki CB1∶ 0.00957 μM; Ki CB2∶ 0.0238 μM; Fuchs et al., 2013) . To put things into perspective, THC displays a modest affinity (Ki: 35-80 nmol) at the CB1 receptor, whilst AM-694, the highest affinity molecule within the synthetic cannabimimetic group (SC, "Spice," and "K2") displays a Ki: 0.1 nmol (Fattore, 2016) . Indeed, SC (Schifano et al., 2015 (Schifano et al., , 2016 There are a number of possible limitations of this study; a multilingual analysis of a larger sample of websites could have provided better levels of information. Furthermore, only publicly available websites/ fora were monitored here, and further data of interest could possibly have been identified by the analysis of the "deep web"/"dark net" material (Orsolini et al., 2015) . We made no Magnolia purchase attempts; hence, one could argue about the product content/dosage being delivered. Overall, anecdotal reports are only partially reliable, and it may be inappropriate to trust information obtained from the internet without independent verification. Since no peer-reviewed papers relating to Magnolia misuse issues were identified, the present conclusions mainly relied on sources (e.g., websites) characterized by levels of unreliability. Hence, a bias may well have been introduced here, and the manuscript's conclusions should be considered as authors' opinions. Only large-scale, adequately controlled, clinical studies can give a clear indication of a drug characteristics and adverse effects. However, in line with present observations, previous studies from our group (Schifano et al., 2009; Siemann, Specka, Schifano, Deluca, & Scherbaum, 2006) have clearly suggested that the increase in online trafficking/debate about a specific psychoactive drug typically precedes the occurrence of clinical incidents at the population level.
The issue of Magnolia products' misuse may be a reason for concern; consumers may not be made fully aware of the pharmacological activity, and possible medical consequences, of the compound(s) they are ingesting. Furthermore, Magnolia products' misuse may often occur in the context of polydrug intake, and the pharmacodynamics/pharmacokinetics' interactions of magnolol/ THM/honokiol with other substances are not known.
As with any centrally active drug, physicians should carefully evaluate patients for history of drug abuse and observe them for signs of misuse of any products, including Magnolia bark.
